Congress Report: ASCO 2011 - The Neurooncology Perspective

Wick W, Platten M

European Association of NeuroOncology Magazine 2011; 1 (1)
53-54

Homepage:
www.kup.at/journals/eano/index.html

Online Database Featuring Author, Key Word and Full-Text Search
For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH.
to helpful suggestions by Lisa de Angelis on how to improve the analysis.

**Conclusions**

In summary, the talks but also other presentations at this year’s ASCO demonstrated considerable activity in the field. Compared to earlier years, the slots for neurooncology-related topics and presentations are getting wider. The relevance of biomarker assessment and new drug development specifically for brain tumours and conducted by brain tumour specialists is largely recognized. Despite some negative trials and specifically the disappointment with the RTOG0525 trial the community is optimistic that we will have another “Brain Tumour ASCO” in the near future.

**Correspondence to:**
Wolfgang Wick, MD
Department of Neurooncology
Neurology Clinic and National Center for Tumour Diseases
University of Heidelberg
69120 Heidelberg
INF 400
Germany
e-mail: wolfgang.wick@med.uni-heidelberg.de